Overview of recent topics in clinical pharmacology of anticancer agents

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 42, Issue , 1998, Pages

  Egorin, Merrill J ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Anticancer agents; Clinical pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CHEMOTHERAPY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG TARGETING; HUMAN; METHODOLOGY; MODEL; POPULATION MODEL; PRIORITY JOURNAL; TECHNIQUE;

EID: 0031713410     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051076     Document Type: Conference Paper

References (78)

1. Albin N, Massade L, Gouyette A (1997) Value and applications of pharmacogenetics in oncology and hematology. Bull Cancer 84:643
2. Allerheiligen S, Johnson R, Hatcher B, Freeman K, Tarassoff P, Voi M, Dorr A (1994) Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc Am Soc Clin Oncol 12:136
3. Anderson LW, Ludeman SM, Colvin OM, Grochow LB, Strong JM (1995) Quantitation of 4-hydroxycyclophosphamide/aldophosphamide, an activated metabolite of cyclophosphamide. J Chromatogr B Biomed Appl 667:247
4. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM (1996) Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2:1481
5. Arneson D, Evans E, Kovatch R, Moore R, Morton T, Tomaszewski J, Smith AC (1995) Preclinical toxicology and pharmacology of flavopiridol (NSC-649890) in rats and dogs. Proc Am Assoc Cancer Res 36:366
6. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835
7. Beal SL, Sheiner LB (1989) NONMEM User's Guides. NONMEM Project Group, University of California, San Francisco
8. Bukowski RM (1996) Amifostine (Ethyol): dosing, administration and patient management guidelines. Eur J Cancer 4:S46
9. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formulation based on renal function. J Clin Oncol 7:1748
10. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R (1995) Prediction of carbolatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573
11. Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colven OM, Grochow LB (1995) Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 55:810
12. Collins JM (1996) Pharmacokinetics and clinical monitoring. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy, 2nd edn. Lippincott-Raven, Philadelphia, p 17
13. Colvin M (1982) The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 9:2
14. Constin D, Potmesil M (1994) Preclinical and clinical development of camptothecins. Adv Pharmacol 29B:51
15. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739
16. D'Argenio DZ, Schumitsky A (1990) ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulation Resource, University of Southern California
17. Egorin MJ, Rosen MD, Sridhara R, Sensenbrenner L, Cottler-Fox M (1997) Plasma concentrations and pharmacokinetics of dimethylsufoxide and its metabolites in patients undergoing peripheral stem cell transplant. J Clin Oncol (in press)
18. 1. Cancer Res 45:6502
19. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of carboplatin in patients with impaired renal function. Cancer Res 44:5432
20. Ekstrom PO, Andersen A, Saeter G, Giercksky KE, Sirdal L (1997) Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Cancer Chemother Pharmacol 39:267
21. Ekstrom PO, Andersen A, Warren DJ, Giercksky KE, Sirdal L (1996) Determination of extracellular methorexate tissue levels by microdialysis in a rat model. Cancer Chemother Pharmacol 37:394
22. Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J (1994) A phase I trial of doxorubicin (D) and PSC833: a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:134
23. Ershler WB, Longo DL (1997) Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89:1489
24. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W (1990) Cellular ARA-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95
25. Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am 275:150
26. Ghazal-Aswad S, Calvert AH, Newell DR (1996) A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37:429
27. Grunewald R, Abbruzzese JL, Tarassaff P, Plunkett W (1991) Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258
28. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406
29. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723
30. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590
31. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetic of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44:1693
32. Harrison M, Tomlinson D, Stewart S (1995) Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914
33. Hawtof FA, Egorin MJ (1991) Evaluation of a new program for population of PK/PD analysis applied to simulated phase I data (abstract). Clin Pharmacol Ther 49:153
34. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumor efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639
35. Hellman K (1996) Cardioprotection by dexrazoxane (Cardioxane; CRF 187): progress in supportive care. Support Care Cancer 4:305
36. Holford NHG, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16:143
37. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM (1995) Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 36:107
38. Janknegt R (1996) Liposomal formulations of cytotoxic drugs. Support Care Cancer 4:298
39. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520
40. Juliano RL, Akhtar S (1992) Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev 2:165
41. Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57:325
42. Kaul S, Srinival NR, Mummaneni V, Igwemezie LN, Barbhaiya RH (1996) Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Semin Oncol 23 (6 Suppl 13):23
43. Kinirons MT, Crome P (1997) Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 33:302
44. 3H-Taxol in the Sprague-Dawley rat. Drug Metab Dispos 22:254
45. Kobayashi K, Jodrell DI, Ratain MJ (1993) Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. In: Workman P, Graham MA (ed) Pharmacokinetics and cancer chemotherapy. Imperial Cancer Research Fund Cold Spring Harbor Laboratory Press, p 51
46. Liang MD, Dahut W, Quinn MF, Harold N, Arbuck SG, Chen A, Hamilton JM, Sorensen JM, Allegra CJ, Grem JL, Takimoto CH (1996) Preclinical and clinical studies of a new colloidal dispersion formulation of 9-amino-camptothecin. Proc Am Assoc Cancer Res 37:432
47. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP (1995) Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13:1958
48. Muller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blochl-Daum B (1997) 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57:2598
49. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB (1996) Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062
50. Omer CA, Anthony NJ, Buser-Doepner CA, Burkhardt AL, deSolms SJ, Dinsmore CJ, Gibbs JB, Hartman GD, Koblan KS, Lobell RB, Oliff A, Williams TM, Kohl NE (1997) Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. Biofactors 6:359
51. Parkinson DR, Arbuck SG, Moore T, Pluda JM, Christian MC (1994) Clinical development of anticancer agents from natural products. Stem Cells 12:30
52. Ratain MJ, Vogelzang NJ (1987) Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 71:935
53. Reeves HW, Newman RA, Hutto T, Madden T (1997) High-performance capillary electrophoresis measurement of dolastatin-10. J Chromatogr B Biomed Appl 693:451
54. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JI, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156
55. Rifkind RA, Richon VM, Marks PA (1996) Induced differentiation, the cell cycle, and the treatment of cancer. Pharmacol Ther 69:97
56. Rislchin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF (1996) Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88:1297
57. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004
58. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowell RD, Pittman KA, Spector S (1992) Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81:309
59. Shay JW, Wright WE (1996) Telomerase activity in human cancer. Curr Opin Oncol 8:66
60. Sheiner LB (1984) The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15:153
61. Sinkule JA, Evans WE (1983) High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside, and some related nucleosides. J Chromatogr 274:87
62. Slavik M, Wu J, Riley C (1993) Salivary excretion of anticancer drugs. Ann NY Acad Sci 694:319
63. Sonneveld SP, Marie JP, Laburte C, Schoester M (1994) Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Am Assoc Cancer Res 35:359
64. Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265
65. Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Yamakido M (1997) Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol 40:449
66. Tonkinson JL, Stein CA (1996) Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest 14:54
67. Venitz J (1995) Pharmacokinetic-pharmacodynamic modeling of reversible drug effects. In: Derendorf H, Hochhaus G (eds) Handbook of pharmacokinetic/pharmacodynamic correlation. CRC Press, Boca Raton, London, Tokyo, p 1
68. Venook AP, Egorin MJ, Brown TD, Batist G, Budman DR, Rosner GL, Jahan TM, Schilsky RL (1994) Paclitaxel (Taxol) in patients with liver dysfunction (CALGB 9264). Proc Am Soc Clin Oncol 13:139
69. Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentrations in the intact animal and man. J Theor Biol 20:171
70. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439
71. Warner DL, Burke TG (1997) Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of campothecin anticancer drugs. J Chromatogr B Biomed Appl 691:161
72. Webster LK, Crinis NA, Morton CG, Millward MJ (1996) Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmacol 37:499
73. Weiss RB, Donehower RC, Wiemik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263
74. Wells P, Harte RJ, Price P (1996) Positron emission tomography: a new investigational area for cancer research. Clin Oncol (R Coll Radiol) 8:7
75. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE (1995) Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13:1985
76. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15:61
77. Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624
78. Zamboni W, Houghton P, Hulstein J, Crom W, Thompson J, Cheshire P, Stewart C (1997) Relationship between tumor extracellular fluid (ECF) exposure to topotecan (TPT) and tumor response in human neuroblastoma xenografts. Proc Am Assoc Cancer Res 38:305